PCN323 Health Status/Utilities in Adult Patients with Germline BRCA1/2 Mutated (GBRCA1/2MUT) HER2− Advanced Breast Cancer (ABC) Treated with POLY(ADP-RIBOSE) Polymerase Inhibitors (PARPI) Versus Chemotherapy in a Real World (RW) Setting

Journal article

Peer reviewed

R Mahtani, A Niyazov, K Lewis, J Pike, A Rider, B Arondekar and M.P Lux

Value in health, Vol.23, pp.S479-S479

2020-12

Metrics

10 Record Views

Title: PCN323 Health Status/Utilities in Adult Patients with Germline BRCA1/2 Mutated (GBRCA1/2MUT) HER2− Advanced Breast Cancer (ABC) Treated with POLY(ADP-RIBOSE) Polymerase Inhibitors (PARPI) Versus Chemotherapy in a Real World (RW) Setting
Creators: R Mahtani - Sylvester Cancer Center, University of Miami, Deerfield Beach, FL, USA
A Niyazov - Pfizer Inc., New York, NY, USA
K Lewis - Adelphi Real World, Bollington, UK
J Pike - Adelphi Real World, Bollington, UK
A Rider - Adelphi Real World, Bollington, UK
B Arondekar - Pfizer Inc., Collegeville, PA, USA
M.P Lux - Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen- und Kinderklinik St. Louise, Paderborn, Germany
Publication Details: Value in health, Vol.23, pp.S479-S479
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031600589702976